Cellectricon has appointed David Burns as the company's new chief executive officer (CEO) and president to expand screening solutions for drug discovery and cell-based research.
David served various management positions at GE Healthcare, Cyntellect, Renishaw Diagnostics, Imaging Research, BioSignal Packard and Pharmacia / LKB.
Cellectricon provides life sciences solutions to discover services solving problems in drug discovery & cell based research.
Cellectricon’s Cellaxess HT System is used for high throughput transfection for genomic screening and the new Dynaflow HT System advances ion channel drug discovery.
Cellectricon CEO David Burns said he will focus on providing strategic, operational, and customer relationship continuity.
"This will ensure that our customers can depend on Cellectricon to accelerate their drug discovery and biological research by continued development of new products and services, as well as an outstanding customer support," Burns said.